Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
December 07 2020 - 7:21AM
Repligen Corporation (NASDAQ: RGEN) today announced that it has
commenced an underwritten public offering of 1.5 million shares of
its common stock. In addition, Repligen Corporation expects to
grant the underwriters a 30-day option to purchase up to an
additional 225,000 shares of its common stock in connection with
the proposed public offering. All shares of common stock will be
offered by Repligen Corporation. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed or as to the actual size or
terms of the offering.
Repligen Corporation intends to use the net
proceeds from this offering for working capital and other general
corporate purposes. Net proceeds from this offering may also be
used to fund possible acquisitions of, or investments in,
complementary businesses, products, services and technologies.
Repligen has not entered into any agreements or commitments with
respect to any acquisitions or investments at this time.
J.P. Morgan Securities LLC and Stifel, Nicolaus
& Company, Incorporated are acting as joint book-running
managers for the offering. Craig-Hallum Capital Group, Stephens
Inc., SVB Leerink LLC and William Blair are acting as co-managers
for the offering.
These securities will be issued and sold pursuant
to an automatically effective shelf registration statement
(including a base prospectus) that was previously filed with the
Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement relating to this offering will be filed with
the SEC (together with such base prospectus, the “Prospectus”).
Before investing in the common stock, investors should read the
Prospectus, including the documents incorporated by reference
therein, and any free writing prospectus related to this offering.
These documents may be freely obtained by visiting EDGAR on the SEC
website at www.sec.gov. Alternatively, copies may be obtained, when
available, from J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com and from Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, California 94104, by
telephone at (415) 364-2720, or by email at
syndprospectus@stifel.com.
The offering will be made only by means of a
prospectus. This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Repligen
CorporationRepligen Corporation is a global life
sciences company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. Our primary
customers are biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, Massachusetts, with
additional administrative and manufacturing operations worldwide.
The majority of our manufacturing sites are located in the U.S.
(California, Massachusetts, New Jersey and New York), and outside
of the U.S. we have sites in Estonia, Germany, Ireland, the
Netherlands and Sweden.
Cautionary Language Concerning
Forward-Looking StatementsThis press release contains
forward-looking statements regarding our future business
expectations, which are subject to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that statements in this press release which are not
strictly historical statements constitute forward-looking
statements, including, without limitation, statements regarding the
size of the proposed offering, completion of the proposed offering
and the anticipated use of proceeds of the proposed offering,
constitute forward-looking statements identified by words like
“believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,”
or “could” and similar expressions. Such forward-looking statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Repligen’s most recent Annual Report on
Form 10-K for the year ended December 31, 2019 and in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2020 on file
with the Securities and Exchange Commission and the other reports
that Repligen periodically files with the Securities and Exchange
Commission. Actual results may differ materially from those
Repligen contemplated by these forward-looking statements. These
forward-looking statements reflect management’s current views and
Repligen does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date hereof except as required
by law.
Source: Repligen CorporationSondra Newman Global
Head of Investor Relationssnewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024